Obsidian Therapeutics aims to show its TIL cell therapy has advantages over an Iovance Biotherapeutics TIL therapy marketed for treating melanoma. Obsidian’s merger with Galera Therapeutics will give it a public listing and a private placement to support clinical development of the combined company’s cancer drug pipeline.
The post Obsidian, Galera Merger Comes With $350M Infusion for Cancer Drug Trials appeared first on MedCity News.
